Searching...
Flashcards in this deck (60)
  • What are the sources of hits and leads in drug discovery?

    Synthetic libraries, natural products, screening of compound libraries.

    drug_discovery sources
  • What do legacy libraries contain?

    Compounds from previous discovery campaigns.

    libraries legacy
  • What are combinatorial libraries?

    Libraries created through combinatorial synthesis techniques.

    libraries combinatorial
  • What are DNA-encoded libraries?

    Libraries where compounds are linked to DNA tags for identification.

    libraries dna
  • What is diversity-oriented synthesis?

    A method to create diverse sets of compounds for screening.

    synthesis diversity
  • What is the benefit of using natural products in drug discovery?

    They show biological activity and necessary properties of clinical candidates.

    natural_products benefits
  • How can drug discovery projects be initiated without a chemical starting point?

    Through screening of compound libraries to find chemical starting points.

    drug_discovery screening
  • What does high throughput screening (HTS) allow?

    Testing tens to hundreds of millions of compounds simultaneously.

    hts screening
  • What are the two types of library screening?

    Diversity and targeted compound libraries.

    screening types
  • What is a diversity library?

    A random set of compounds with good drug-like properties, no design basis for activity.

    libraries diversity
  • What is a targeted library?

    A set of compounds designed to possess structural features suggesting biological activity.

    libraries targeted
  • Who defined drug-like properties?

    Chris Lipinski.

    drug_properties lipinski
  • What are acceptable ADME/tox properties?

    Properties that allow compounds to survive human Phase 1 trials.

    adme toxicity
  • What affects the physico-chemical properties of a compound?

    The physical environment and interactions with proteins.

    physico-chemical properties
  • How can medicinal chemists control PK and toxicity?

    By modifying the chemical structure of the compound.

    medicinal_chemistry control
  • What are important physicochemical properties?

    Lipophilicity, solubility, and ability to cross lipid membranes.

    physicochemical properties
  • What is the goal of modifying chemical structure in drug discovery?

    To change the drug's pharmacokinetics and toxicity.

    modification pharmacokinetics
  • What are Lipinski's Rules used for?

    To assess drug-like properties of compounds.

    lipinski drug properties
  • What is a key factor in poor absorption according to Lipinski's Rules?

    More than 5 hydrogen bond donors.

    absorption lipinski rules
  • What molecular weight (MWt) indicates poor absorption risk?

    MWt greater than 500.

    absorption mwt rules
  • What logP value suggests poor absorption?

    LogP greater than 5.

    absorption logp rules
  • What is the maximum number of hydrogen bond acceptors for good absorption?

    No more than 10 hydrogen bond acceptors.

    absorption hydrogen rules
  • What is logP a measure of?

    Lipophilicity.

    logp lipophilicity
  • What does violating Lipinski's Rules imply about absorption?

    Increased likelihood of poor absorption.

    absorption lipinski rules
  • What is the goal of selecting lead-like compounds?

    To avoid major liabilities in drug development.

    lead-like compounds drug development
  • What is the ideal range for cLogP in oral drug-like compounds?

    1 ≤ cLogP ≤ 4.

    oral drugs clogp
  • What is the ideal molecular weight range for oral drug-like compounds?

    250 ≤ MWt ≤ 400.

    oral drugs mwt
  • What is a diversity library in drug discovery?

    A collection of previously synthesized compounds for future testing.

    diversity library drug discovery
  • What is the average success rate for compounds to become drugs?

    1 in 10,000 compounds.

    success rate drugs
  • What is a common issue with high throughput screening of diversity libraries?

    Very low hit rate.

    high-throughput screening hit rate
  • What is the typical molecular weight range for active site HTS screening ligands?

    MWt 400-500.

    hts screening ligands mwt
  • What is often necessary for compounds with poor fit to targets in classical HTS?

    Optimization through deconstruction.

    optimization classical hts
  • What is the MWt range for active site HTS screening ligands?

    400-500

    hts ligands
  • What are the issues with classical HTS?

    Poor fit to target; Low affinity; High starting MWt; Potential poor ADMET

    hts challenges
  • What is deconstruction in drug discovery?

    Optimizing compounds by altering functional groups to enhance affinity and potency.

    deconstruction optimization
  • What physicochemical properties should be considered in compound library design?

    cLogP, MWt, predicted solubility

    compound_design properties
  • What is 'drug-likeness' or 'lead-likeness'?

    Criteria that determine how suitable a compound is for drug development.

    drug-likeness lead-likeness
  • What are synthetic libraries in drug discovery?

    Libraries containing compounds from previous discovery campaigns.

    synthetic_libraries drug_discovery
  • What is a targeted library?

    A library containing compounds designed for specific biological targets.

    targeted_library screening
  • What is a key example of a targeted library?

    Compounds designed for HIV protease, which is an aspartic acid protease.

    hiv protease
  • What is the characteristic sequence of the HIV protease active site?

    Asp-Thr-Gly (Asp25, Thr26, Gly27)

    hiv protease active_site
  • What role do the Asp25 residues play in HIV protease?

    They act as catalytic residues where inhibitors bind.

    hiv protease catalytic_residues
  • What did the rational approach in HIV protease inhibitor search involve?

    Using structural similarities and key molecular interactions for candidate selection.

    hiv inhibitors rational_design
  • What is Darunavir?

    An HIV-1 protease inhibitor with high affinity for both HIV-1 protease and renin.

    darunavir hiv inhibitors
  • What new idea arose from the study of Darunavir?

    The idea of combination therapy for HIV treatment.

    combination_therapy hiv
  • What is the significance of structural similarities in drug discovery?

    They help in selecting candidates for screening based on interactions with targets.

    structural_similarity drug_discovery
  • What is Ro 5-3335 inactive as?

    An anti-anxiety drug

    pharmacology hiv
  • What activity did Ro 5-3335 possess?

    Anti-HIV activity

    pharmacology hiv
  • What is Ro 24-7429?

    A Tat antagonist

    pharmacology hiv
  • What is the role of the Tat protein?

    Essential for HIV viral replication

    pharmacology hiv
  • What was Nevirapine originally prepared as?

    A muscarinic M3 receptor antagonist

    pharmacology hiv
  • What type of inhibitor is Nevirapine?

    Non-nucleoside reverse transcriptase inhibitor

    pharmacology hiv
  • What was Topiramate initially prepared as?

    A synthetic intermediate

    pharmacology epilepsy
  • What activity did Topiramate demonstrate?

    Anticonvulsant activity

    pharmacology epilepsy
  • When was Topiramate marketed as an anti-epileptic drug?

    ~20 years after its original synthesis

    pharmacology epilepsy
  • When was Topiramate approved by the FDA?

    In 1996

    pharmacology epilepsy
  • What additional approval did Topiramate receive in 2004?

    Prevention of migraine in adults

    pharmacology migraine
  • What combination was approved for Topiramate in 2012?

    Extended-release formulation with phentermine

    pharmacology weight_management
  • What is the hit rate for diversity library screening?

    Remains quite low

    pharmacology drug_discovery
  • What do pharmaceutical companies want access to?

    More chemically diverse compounds

    pharmacology drug_discovery